Form 4: Tvardi Therapeutics CFO Acquires Stock Options Following Merger

Avi Daniel Conn, CFO of Tvardi Therapeutics, reports acquisition of stock options following the merger with Legacy Tvardi.

Summary

• Avi Daniel Conn, the Chief Financial Officer of Tvardi Therapeutics, filed a Form 4 indicating changes in beneficial ownership.
• The report details the acquisition of 89,053 employee stock options with an exercise price of $4.70, granted on April 15, 2025.
• These options were received in exchange for stock options to acquire 664,000 shares of Legacy Tvardi common stock at an exercise price of $0.63 per share, pursuant to a merger agreement.
• The merger involved CT Convergence Merger Sub, Inc., a wholly-owned subsidiary of Tvardi Therapeutics, merging with Legacy Tvardi, with Legacy Tvardi surviving as a wholly-owned subsidiary.
• The options vest over time, with 25% vesting on the one-year anniversary of the vesting commencement date and the remaining balance vesting in 36 successive equal monthly installments.

Sentiment

Score: 6

Explanation: Neutral sentiment as the document primarily reports a routine transaction related to executive compensation following a merger.

Positives

• The acquisition of stock options by the CFO could indicate confidence in the company's future performance.

Industry Context

Form 4 filings are standard practice and provide transparency into the transactions of company insiders, allowing investors to track ownership changes and potential alignment of interests.

Stakeholder Impact

• The granting of stock options aligns the CFO's interests with those of the shareholders.

Key Dates

Keywords

Tvardi Therapeutics, Form 4, stock options, merger, beneficial ownership, CFO, Avi Daniel Conn, Legacy Tvardi